MEDICLIN AG (MED.DE) Stock Fundamental Analysis

FRA:MED • DE0006595101

3.72 EUR
+0.02 (+0.54%)
Last: Feb 20, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

6

Taking everything into account, MED scores 6 out of 10 in our fundamental rating. MED was compared to 29 industry peers in the Health Care Providers & Services industry. MED has an excellent profitability rating, but there are some minor concerns on its financial health. MED scores decently on growth, while it is valued quite cheap. This could make an interesting combination. These ratings could make MED a good candidate for value investing.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • In the past year MED was profitable.
  • In the past year MED had a positive cash flow from operations.
  • In multiple years MED reported negative net income over the last 5 years.
  • MED had a positive operating cash flow in each of the past 5 years.
MED.DE Yearly Net Income VS EBIT VS OCF VS FCFMED.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M 80M 100M

1.2 Ratios

  • MED has a Return On Assets of 3.85%. This is in the better half of the industry: MED outperforms 72.41% of its industry peers.
  • MED has a better Return On Equity (14.15%) than 79.31% of its industry peers.
  • MED's Return On Invested Capital of 7.06% is fine compared to the rest of the industry. MED outperforms 79.31% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for MED is below the industry average of 6.14%.
  • The 3 year average ROIC (3.46%) for MED is below the current ROIC(7.06%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 3.85%
ROE 14.15%
ROIC 7.06%
ROA(3y)0.85%
ROA(5y)0.34%
ROE(3y)3.39%
ROE(5y)1.18%
ROIC(3y)3.46%
ROIC(5y)2.35%
MED.DE Yearly ROA, ROE, ROICMED.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5 -5 10

1.3 Margins

  • MED's Profit Margin of 4.40% is fine compared to the rest of the industry. MED outperforms 72.41% of its industry peers.
  • In the last couple of years the Profit Margin of MED has grown nicely.
  • With a decent Operating Margin value of 8.52%, MED is doing good in the industry, outperforming 72.41% of the companies in the same industry.
  • MED's Operating Margin has improved in the last couple of years.
  • MED has a better Gross Margin (84.08%) than 86.21% of its industry peers.
  • MED's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 8.52%
PM (TTM) 4.4%
GM 84.08%
OM growth 3Y67.11%
OM growth 5Y19.19%
PM growth 3Y148.06%
PM growth 5Y18.19%
GM growth 3Y0.37%
GM growth 5Y0.18%
MED.DE Yearly Profit, Operating, Gross MarginsMED.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • MED has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • The number of shares outstanding for MED remains at a similar level compared to 1 year ago.
  • MED has about the same amout of shares outstanding than it did 5 years ago.
  • MED has a better debt/assets ratio than last year.
MED.DE Yearly Shares OutstandingMED.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
MED.DE Yearly Total Debt VS Total AssetsMED.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

  • Based on the Altman-Z score of 1.59, we must say that MED is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of 1.59, MED perfoms like the industry average, outperforming 41.38% of the companies in the same industry.
  • The Debt to FCF ratio of MED is 9.63, which is on the high side as it means it would take MED, 9.63 years of fcf income to pay off all of its debts.
  • The Debt to FCF ratio of MED (9.63) is better than 62.07% of its industry peers.
  • A Debt/Equity ratio of 1.69 is on the high side and indicates that MED has dependencies on debt financing.
  • MED has a worse Debt to Equity ratio (1.69) than 65.52% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.69
Debt/FCF 9.63
Altman-Z 1.59
ROIC/WACC1.44
WACC4.91%
MED.DE Yearly LT Debt VS Equity VS FCFMED.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M 400M

2.3 Liquidity

  • A Current Ratio of 1.93 indicates that MED should not have too much problems paying its short term obligations.
  • MED has a better Current ratio (1.93) than 89.66% of its industry peers.
  • A Quick Ratio of 1.89 indicates that MED should not have too much problems paying its short term obligations.
  • The Quick ratio of MED (1.89) is better than 93.10% of its industry peers.
Industry RankSector Rank
Current Ratio 1.93
Quick Ratio 1.89
MED.DE Yearly Current Assets VS Current LiabilitesMED.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • MED shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 414.18%, which is quite impressive.
  • MED shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 20.79% yearly.
  • Looking at the last year, MED shows a small growth in Revenue. The Revenue has grown by 3.40% in the last year.
  • Measured over the past years, MED shows a small growth in Revenue. The Revenue has been growing by 2.19% on average per year.
EPS 1Y (TTM)414.18%
EPS 3Y157.01%
EPS 5Y20.79%
EPS Q2Q%7.67%
Revenue 1Y (TTM)3.4%
Revenue growth 3Y3.65%
Revenue growth 5Y2.19%
Sales Q2Q%7.96%

3.2 Future

  • MED is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.30% yearly.
  • The Revenue is expected to grow by 3.42% on average over the next years.
EPS Next Y78.05%
EPS Next 2Y34.35%
EPS Next 3Y22.3%
EPS Next 5YN/A
Revenue Next Year5.05%
Revenue Next 2Y3.88%
Revenue Next 3Y3.42%
Revenue Next 5YN/A

3.3 Evolution

  • The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
MED.DE Yearly Revenue VS EstimatesMED.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M 800M
MED.DE Yearly EPS VS EstimatesMED.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.2 0.4 0.6

More info and screens

Find the best growth stocksShow best growing peers

9

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 5.03 indicates a rather cheap valuation of MED.
  • Based on the Price/Earnings ratio, MED is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
  • The average S&P500 Price/Earnings ratio is at 26.99. MED is valued rather cheaply when compared to this.
  • A Price/Forward Earnings ratio of 4.98 indicates a rather cheap valuation of MED.
  • Based on the Price/Forward Earnings ratio, MED is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
  • MED is valuated cheaply when we compare the Price/Forward Earnings ratio to 28.06, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 5.03
Fwd PE 4.98
MED.DE Price Earnings VS Forward Price EarningsMED.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • MED's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. MED is cheaper than 96.55% of the companies in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of MED indicates a rather cheap valuation: MED is cheaper than 89.66% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 3.8
EV/EBITDA 2.87
MED.DE Per share dataMED.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of MED may justify a higher PE ratio.
  • MED's earnings are expected to grow with 22.30% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.06
PEG (5Y)0.24
EPS Next 2Y34.35%
EPS Next 3Y22.3%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

2

5. Dividend

5.1 Amount

  • With a Yearly Dividend Yield of 1.08%, MED has a reasonable but not impressive dividend return.
  • MED's Dividend Yield is comparable with the industry average which is at 1.80.
  • With a Dividend Yield of 1.08, MED pays less dividend than the S&P500 average, which is at 1.81.
Industry RankSector Rank
Dividend Yield 1.08%

5.2 History

Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
MED.DE Yearly Dividends per shareMED.DE Yearly Dividends per shareYearly Dividends per share 2019 2025 0.01 0.02 0.03 0.04

5.3 Sustainability

DPN/A
EPS Next 2Y34.35%
EPS Next 3Y22.3%
MED.DE Yearly Income VS Free CF VS DividendMED.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M 80M

More info and screens

Find the best dividend stocksShow peers with best dividend

MEDICLIN AG

FRA:MED (2/20/2026, 7:00:00 PM)

3.72

+0.02 (+0.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-04
Earnings (Next)03-26
Inst Owners0.96%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap176.70M
Revenue(TTM)797.34M
Net Income(TTM)35.05M
Analysts80
Price Target5.87 (57.8%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.08%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)22.34%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)9.77%
EPS NY rev (3m)16.8%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.48%
Valuation
Industry RankSector Rank
PE 5.03
Fwd PE 4.98
P/S 0.22
P/FCF 3.8
P/OCF 1.83
P/B 0.71
P/tB 0.79
EV/EBITDA 2.87
EPS(TTM)0.74
EY19.89%
EPS(NY)0.75
Fwd EY20.09%
FCF(TTM)0.98
FCFY26.32%
OCF(TTM)2.04
OCFY54.71%
SpS16.79
BVpS5.21
TBVpS4.7
PEG (NY)0.06
PEG (5Y)0.24
Graham Number9.32
Profitability
Industry RankSector Rank
ROA 3.85%
ROE 14.15%
ROCE 9.1%
ROIC 7.06%
ROICexc 9.61%
ROICexgc 10.05%
OM 8.52%
PM (TTM) 4.4%
GM 84.08%
FCFM 5.83%
ROA(3y)0.85%
ROA(5y)0.34%
ROE(3y)3.39%
ROE(5y)1.18%
ROIC(3y)3.46%
ROIC(5y)2.35%
ROICexc(3y)4.47%
ROICexc(5y)3.03%
ROICexgc(3y)4.72%
ROICexgc(5y)3.22%
ROCE(3y)4.46%
ROCE(5y)3.03%
ROICexgc growth 3Y64.29%
ROICexgc growth 5Y26.18%
ROICexc growth 3Y68.25%
ROICexc growth 5Y27.23%
OM growth 3Y67.11%
OM growth 5Y19.19%
PM growth 3Y148.06%
PM growth 5Y18.19%
GM growth 3Y0.37%
GM growth 5Y0.18%
F-Score8
Asset Turnover0.88
Health
Industry RankSector Rank
Debt/Equity 1.69
Debt/FCF 9.63
Debt/EBITDA 3.49
Cap/Depr 96.09%
Cap/Sales 6.29%
Interest Coverage 3.18
Cash Conversion 80.47%
Profit Quality 132.66%
Current Ratio 1.93
Quick Ratio 1.89
Altman-Z 1.59
F-Score8
WACC4.91%
ROIC/WACC1.44
Cap/Depr(3y)56.34%
Cap/Depr(5y)45.08%
Cap/Sales(3y)4.78%
Cap/Sales(5y)4.13%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)414.18%
EPS 3Y157.01%
EPS 5Y20.79%
EPS Q2Q%7.67%
EPS Next Y78.05%
EPS Next 2Y34.35%
EPS Next 3Y22.3%
EPS Next 5YN/A
Revenue 1Y (TTM)3.4%
Revenue growth 3Y3.65%
Revenue growth 5Y2.19%
Sales Q2Q%7.96%
Revenue Next Year5.05%
Revenue Next 2Y3.88%
Revenue Next 3Y3.42%
Revenue Next 5YN/A
EBIT growth 1Y281.51%
EBIT growth 3Y73.21%
EBIT growth 5Y21.8%
EBIT Next Year143.72%
EBIT Next 3Y33.62%
EBIT Next 5YN/A
FCF growth 1Y196.83%
FCF growth 3Y-17.96%
FCF growth 5Y7.78%
OCF growth 1Y96.85%
OCF growth 3Y-0.57%
OCF growth 5Y2.97%

MEDICLIN AG / MED.DE FAQ

What is the ChartMill fundamental rating of MEDICLIN AG (MED.DE) stock?

ChartMill assigns a fundamental rating of 6 / 10 to MED.DE.


Can you provide the valuation status for MEDICLIN AG?

ChartMill assigns a valuation rating of 9 / 10 to MEDICLIN AG (MED.DE). This can be considered as Undervalued.


Can you provide the profitability details for MEDICLIN AG?

MEDICLIN AG (MED.DE) has a profitability rating of 7 / 10.


Can you provide the PE and PB ratios for MED stock?

The Price/Earnings (PE) ratio for MEDICLIN AG (MED.DE) is 5.03 and the Price/Book (PB) ratio is 0.71.


What is the financial health of MEDICLIN AG (MED.DE) stock?

The financial health rating of MEDICLIN AG (MED.DE) is 5 / 10.